Prediction certainty 4/5 debate potential 1/5

Abernethy: Core FDA priorities will be evidence generation, personalized medicine, drug design

Dr. Amy Abernethy · a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer · Feb 26, 2019 · at 35:00

Dr. Amy Abernethy, incoming Principal Deputy Commissioner at the U.S. Food and Drug Administration (FDA), discusses her focus areas upon stepping into her regulatory role.

0:00 / 0:37exact quote · 37.3s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“When I'm at FDA, I will have a trans-FDA remit, so I will need to spend my time and energy working on the things that the FDA needs me to do, and I'm looking forward to learning more and more about that every day. But I know that I'll at least spend some of my personal extra energy on three core areas, one being accelerating evidence generation. I can't work with One Health anymore, but you can sort of hopefully see how I've been thinking about evidence generation for a long time. The second is as it relates to personalized medicine. This has been a core focus for me for a long time as an oncologist, and that's just as a person. And then the third is patient-informed drug design.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

More from Dr. Amy Abernethy

Insight
Abernethy: Testing cancer drugs in dogs saves tens of millions per drug
“The whole message that really I walked away from that conference with was that if we now embedded into the drug development process for human drug development a better understanding of how those drugs performed in dogs, we could save many tens of millions of d…”
Dr. Amy Abernethy Feb 26, 2019 ▶ 7:51 a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Assertion Supported
Abernethy: Lack of pet HIPAA rules simplifies veterinary health data aggregation
“There's no doggy HIPAA. Now, we have to do the right thing by pets and pet owners, and we need to basically only think about using that information in a way that's good for society, for pets and pet owners. But that being said, many of the impediments, as we t…”
Dr. Amy Abernethy Feb 26, 2019 ▶ 13:00 a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Assertion Supported
Abernethy: One Health is Flatiron Health for dogs
“This is flat iron for dogs.”
Dr. Amy Abernethy Feb 26, 2019 ▶ 25:13 a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Assertion Supported
Abernethy: Most FDA applications still arrive as static PDF files
“In fact, the way the majority of our applications still come in is through PDFs or sort of essentially large digital representations of what used to come in on trucks.”
Dr. Amy Abernethy Jan 6, 2020 ▶ 4:00 Food, Drugs, and Tech: 100 years of Public Health
Assertion Partly supported
Dr. Abernethy: Dogs share more conserved biology with humans than mice do
“So there's much more conserved biology between dog and human than mouse and human.”
Dr. Amy Abernethy Feb 26, 2019 ▶ 6:16 a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Insight
Abernethy: Health data platforms must serve clinical users before monetizing data
“So what we saw at Flatiron is you've got to make sure that you take care of oncologists and patients first, and have a mechanism to bring the data in, and then you can get the data ready To have secondary purposes. But if you have that out of order, you've act…”
Dr. Amy Abernethy Feb 26, 2019 ▶ 27:09 a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,000 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.